CN105998086A - Microalgae composition for preventing and treating airway inflammation as well as preparation and application thereof - Google Patents
Microalgae composition for preventing and treating airway inflammation as well as preparation and application thereof Download PDFInfo
- Publication number
- CN105998086A CN105998086A CN201610458777.1A CN201610458777A CN105998086A CN 105998086 A CN105998086 A CN 105998086A CN 201610458777 A CN201610458777 A CN 201610458777A CN 105998086 A CN105998086 A CN 105998086A
- Authority
- CN
- China
- Prior art keywords
- spirulina
- component
- algae
- arthrospira
- airway inflammation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/748—Cyanobacteria, i.e. blue-green bacteria or blue-green algae, e.g. spirulina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
Abstract
The invention provides microalgae composition for preventing and treating airway inflammation as well as a preparation and an application thereof. The microalgae composition is prepared form a component A and a component B in a mass ratio of 10:1-1:10, wherein the component A is spirulina and a variety and mutagenic variety of the spirulina, and the component B is single-spore algae and a variety and mutagenic variety of the single-spore algae. The microalgae composition can be applied to preparation of a medicine for preventing and treating the airway inflammation and particularly a medicine for syndromes of bronchial asthma, chronic obstructive pulmonary disease, acute lung injury and acute respiratory failure.
Description
Technical field
The invention belongs to medical treatment & health field, be specifically related to a kind of prevention and the microalgae compositions for the treatment of airway inflammation and system thereof
Agent and application.
Background technology
Asthma is the chronic respiratory tract disease of a kind of serious harm human health, and its prevalence is in the world in rising
Trend, the whole world there are about 300,000,000 patient's asthmatic patients, and average prevalence is about 4.5%, it is contemplated that by 2025, and whole world asthmatic patient is total
Number is up to 400,000,000.China there are about 2,000 ten thousand asthma patients, and average prevalence is at 0.5%-1%, and in some area, roars in child
Oneself is up to 4.52% to breathe heavily prevalence.The mortality rate of whole world asthma is overall also to be raised, and U.S.'s asthma case fatality rate has reached 5.3%.Roar
Oneself causes the attention of World Health Organization (WHO) and national governments to breathe heavily brought heavy burden.
Airway inflammation is the key factor of asthma, is also the important target spot of asthma preventing and treating.The medicine of clinical treatment asthma
Thing includes glucocorticoid, broxaterol, leukotrienes regulator, theophylline, anticholinergic agent, anti-IgE treatment etc., wherein
Glucocorticoid is the medicine of maximally effective control airway inflammation, is also the first-selection of current clinical treatment asthma, is given by difference
Medicine approach and dosage play the effect controlling or alleviating asthma.But long-term or a large amount of use can cause osteoporosis,
The suppression of hypertension, diabetes, hypothalamus---hypophysis---hypothalamic pituitary adrenal axis, obesity, cataract, epidermatic atrophy are led
Cause dermatoglyph and ecchymosis, myasthenia etc..Find more safe and effective suppression airway inflammation medicine and there is significant social meaning
And clinical value.
Microalgae is as the treasure-house of natural product in nature, containing abundant all kinds of active substances and secondary metabolite,
But further investigation for these kinds and the pharmacological action of various informative activity of microalgae material is the rarest.Pass through document
Investigation finds, has the most tens of kinds of the algae kind of antiinflammatory action, and this laboratory have selected spirulina and monospore through screening premenstruum
Algae is candidate's algae kind, completes exploratory study, and result of study shows: at ovalbumin (OVA) induced mice allergic asthma
Airway inflammation model in, spirulina be used in combination and Micro Algae can reduce lung tissue inflammatory pathologies after sensitized animal antigen is attacked
In histological grading scoring, suppression bronchoalveolar lavage fluid, in inflammatory cell quantity, regulation bronchoalveolar lavage fluid, cytokine and chemotactic factor contain
OVA specific IgE content in amount, minimizing serum；At LPS induced mice mononuclear phagocyte RAW 264.7 inflammatory reaction model
In, be used in combination the lipid extracts of spirulina and Micro Algae can reduce inflammatory factor TNF-α and IL-6 content in born of the same parents' culture fluid,
Suppression cell NF κ B promotees the activation of Inflammatory Pathway.
Summary of the invention
The invention provides the microalgae combination of a kind of prevention and treatment airway inflammatory disorders, using microalgae as natural drug
Source, for airway inflammatory disorders (such as: bronchial asthma, chronic obstructive pulmonary disease, acute lung injury and acute respiratory failure are combined
Close disease etc.) treat and prevent the technical tactic providing new.
The present invention is realized by following technical proposals:
A kind of prevention and the microalgae compositions for the treatment of airway inflammation, including the component A that mass ratio is 10:1 ~ 1:10 and B component；Institute
Stating component A is spirulina and mutation thereof and mutation mutation, and B component is monospore algae and mutation thereof and mutation mutation.
As preference: described component A is 1:1 with the mass ratio of B component.
As preference: in described component A, spirulina includes Arthrospira and Spirullina.
As preference: described Arthrospira include short arthrospira, Jian Shi arthrospira, Gas Vesicle Protein From Arthrospira maxima, transparent arthrospira,
Obtusatus arthrospira, small-sized rotation shape arthrospira, rotation shape arthrospira and small arthrospira.
As preference: described Spirullina includes huge spirulina, Ge Shi spirulina, Qiang Shi spirulina, toroidal
Algae, loose spirulina, loose spirulina, huge spirulina, spirulina maxim, Meng Shi spirulina, Nuo Shi spirulina, seemingly quiver spiral
Algae, spirulina plalensis, seemingly revolve spirulina, Spirulina subaalsa, careful spirulina, compact spiral algae, gentle helix algae, Sa Shi spiral
Algae, mud pool spirulina and purple spirulina.
As preference: in described B component, monospore algae can be replaced micro-plan ball algae, Nitzschia closterium minutissima or Phaeodactylum.
The present invention also provides for comprising the preparation of above-mentioned microalgae compositions, comprises the algae powder and pharmaceutically of component A and B component
Acceptable adjuvant or comprise the fat extract of component A and B component and pharmaceutically acceptable adjuvant；The consumption of described fat extract
Calculate by algae powder equivalent.
As preference: preparation formulation is oral or external preparation.
Invention formulation application in preparation prevention and treatment airway inflammation disease medicament, particularly bronchus is roared
Breathe heavily, chronic obstructive pulmonary disease, application in acute lung injury and acute respiratory failure syndrome medicament.
The Advantageous Effects of the present invention: result of study shows, is used in combination spirulina and Micro Algae has and significantly presses down
The effect of airway inflammation processed.It is embodied in: at the airway inflammation model of ovalbumin (OVA) induced mice allergic asthma
In, spirulina is used in combination and Micro Algae can reduce lung tissue inflammatory pathologies rank scores after sensitized animal antigen is attacked, press down
Cytokine and chemotactic factor content in inflammatory cell quantity in bronchoalveolar lavage fluid processed, regulation bronchoalveolar lavage fluid, reduce in serum
OVA specific IgE content；In LPS induced mice mononuclear phagocyte RAW 264.7 inflammatory reaction model, spiral shell is used in combination
The lipid extracts of rotation algae and Micro Algae can reduce inflammatory factor TNF-α and IL-6 content, suppression cell NF κ B in born of the same parents' culture fluid
Promote the activation of Inflammatory Pathway.
Accompanying drawing explanation
Fig. 1: the impact of the lung tissue inflammatory pathologies rank scores that OVA is induced by microalgae fat extract；
Fig. 2: the microalgae fat extract impact on the inflammatory cell infiltration that OVA induces；
Fig. 3: the impact of Th1 and Th2 cytokine content in the bronchoalveolar lavage fluid that OVA is induced by microalgae fat extract；
Fig. 4: microalgae fat extract is on the impact of OVA specific IgE content in serum；
Fig. 5: microalgae fat extract is on TNF-α in cell culture fluid and the impact of IL-6 content；
The impact on cell NF κ B path of Fig. 6: the microalgae fat extract.
Detailed description of the invention
Embodiment 1:
Taking Gas Vesicle Protein From Arthrospira maxima and monospore algae, carry out proportioning for 10:1 in mass ratio, formulation method is prepared as oral liquid routinely.
Embodiment 2:
Take Obtusatus arthrospira and micro-plan ball algae, carry out proportioning for 5:1 in mass ratio, be prepared as powder according to conventional formulation method.
Embodiment 3:
Take spirulina maxim and Nitzschia closterium minutissima, carry out proportioning for 2:1 in mass ratio, prepare pelletization according to conventional formulation method
Agent.
Embodiment 4:
Take spirulina plalensis and monospore algae, carry out proportioning for 1:1 in mass ratio, be prepared as sublimed preparation according to conventional formulation method.
Embodiment 5:
Take spirulina plalensis and Phaeodactylum, carry out proportioning for 1:2 in mass ratio, according to the preparation of conventional formulation method in flakes
Agent.
Embodiment 6:
Take spirulina plalensis and monospore algae, carry out proportioning for 1:5 in mass ratio, be prepared as hard capsule according to conventional formulation method
Agent.
Embodiment 7:
Take spirulina plalensis and monospore algae, carry out proportioning for 1:10 in mass ratio, be prepared as soft capsule according to conventional formulation method
Agent.
Embodiment 8:
Take spirulina plalensis mutation and monospore algae mutation, carry out proportioning for 1:1 in mass ratio, be prepared as according to conventional formulation method
Granule.
Embodiment 9:
Take spirulina plalensis mutation mutation and monospore algae mutation mutation, carry out proportioning for 1:1 in mass ratio, according to conventional formulation side
Method is prepared as granule.
Embodiment 10:
Taking spirulina plalensis and monospore algae, carry out proportioning for 10:1 in mass ratio, 10 times (v/w) measures dehydrated alcohol, and 70 DEG C are extracted 2
Secondary, each 1 hour.United extraction liquid, reclaims ethanol, and 50 DEG C of low pressure are dried 12 hours, obtain extract；Said extracted thing is pressed
More solito formulation method is prepared as lotion.
Embodiment 11:
Taking Gas Vesicle Protein From Arthrospira maxima and micro-plan ball algae, carry out proportioning for 1:1 in mass ratio, 10 times (v/w) measures dehydrated alcohol, 70 DEG C of extractions
2 times, each 1 hour.United extraction liquid, reclaims ethanol, and 50 DEG C of low pressure are dried 12 hours, obtain extract；By said extracted thing
It is prepared as unguentum according to conventional formulation method.
Embodiment 12:
Taking spirulina maxim and Phaeodactylum, carry out proportioning for 1:10 in mass ratio, 10 times (v/w) measures dehydrated alcohol, 70 DEG C
Extract 2 times, each 1 hour.United extraction liquid, reclaims ethanol, and 50 DEG C of low pressure are dried 12 hours, obtain extract；Carry above-mentioned
Take thing and be prepared as liniment according to conventional formulation method.
Pharmacological experiment
One, zoopery confirms that (raw material is embodiment 10 or 11 in the pharmacological action of airway inflammation caused by microalgae fat extract antagonism OVA
Or extract in 12)
Female Babl/c mice is randomly divided into blank group, ovalbumin (OVA) matched group, microalgae fat extract little, in, big
Dosage group and dexamethasone positive controls, continuous processing 12 weeks, observe the suppression to airway inflammation caused by OVA of the microalgae fat extract
Effect.Result is as follows:
(1) microalgae fat extract inhibits the airway inflammation that OVA induces
As it is shown in figure 1, normal group lung tissue HE section in, air flue tube chamber is smooth, mucosa without edema, the most a small amount of inflammatory cell soak
Profit；In the section of model group lung tissue HE, airway walls thickens, a mucosa wrinkle ancient piece of jade, round, flat and with a hole in its centre increases, luminal stenosis, and alveolar wall edema is congested, a large amount of
Inflammatory cell infiltration.In positive controls and the section of microalgae fat extract heavy dose group, wall inflammatory cell infiltration degree substantially alleviates.
According to " lung tissue inflammatory pathologies rank scores standard after the attack of sensitized animal antigen ", observe mouse lung tissue rank scores.
Compared with blank group, model group mouse lung tissue inflammatory score significantly improves (P < 0.01)；Microalgae fat extract is little, middle and high
Dosage group and dexamethasone in treatment group significantly reduce inflammatory score (P < 0.01, P < 0.05).
(2) microalgae fat extract inhibits the inflammatory cell infiltration that OVA induces
As in figure 2 it is shown, compared with blank group, in OVA model group mice bronchoalveolar lavage fluid, inflammatory cell content is significantly raised
(P < 0.01).Compared with OVA model group matched group, microalgae fat extract can reduce inflammatory cell sum and acidophilia by dose dependent
Granulocyte number (P < 0.01), microalgae fat extract heavy dose group can reduce neutrophilic granulocyte, macrophage (P < 0.01, P <
0.05).
(3) Th1 and Th2 cytokine content in microalgae fat extract scalable mouse asthmatic model bronchoalveolar lavage fluid
As it is shown on figure 3, compared with blank group, IL-4, IL-5 and IFN-γ content in OVA model group mice bronchoalveolar lavage fluid
Notable rising (p ＜ 0.01)；Compared with OVA model group, microalgae fat extract dose-dependently significantly reduces suffers from mouse asthma
IL-4, IL-5 content (p ＜ 0.01, p ＜ 0.05) in bronchoalveolar lavage fluid, raises IL-10, IFN-γ content (p ＜ 0.01).
(4) microalgae fat extract reduces OVA Serum specificity immunoglobulin E content in serum
As shown in Figure 4, result (3) show that microalgae fat extract can significantly regulate main Th1 and Th2 of mice of OVA induction should
Answer.In order to further determine that the regulation effect to internal OVA specificity T h2 response of the microalgae fat extract, we use enzyme linked immunological
The method of adsorption experiment checks, the target of detection is the content of the OVA Serum specificity immunoglobulin E in serum.Final
Existing, microalgae fat extract can inhibit the content of OVA specific IgE on the premise of not changing total IgE significantly.
Two, test cell line confirms microalgae fat extract can to improve caused by LPS Cellular inflammatory reaction (raw material is embodiment 10 or 11
Or extract in 12).
Mouse monokaryon macrophage RAW 264.7 is divided into blank group, LPS matched group, microalgae fat extract little, in,
Heavy dose of group, observes under LPS stimulation, the protective effect to cell of the microalgae fat extract.Result is as follows:
(1) TNF-α and IL-6 content during microalgae fat extract reduces born of the same parents' culture fluid
As it is shown in figure 5, compared with blank group, in LPS model group cell culture fluid, TNF-α and IL-6 content significantly raise (p
＜ 0.01)；Compared with LPS model group, microalgae fat extract middle and high dosage group reduces TNF-α (p ＜ 0.01) in cell culture fluid,
Microalgae fat extract high dose group reduces IL-6 content (p ＜ 0.01) in cell culture fluid.
(2) microalgae fat extract suppression cell NF κ B signal pathway activated
As shown in Figure 6, compared with blank group, LPS model group p-IKK expresses notable rising (p ＜ 0.01), and I κ B expresses aobvious
Write and reduce (p ＜ 0.01)；Compared with LPS model group, microalgae fat extract high dose group significantly reduces p-IKK and expresses (p ＜ 0.01),
Microalgae fat extract high dose group significantly raises I κ B and expresses (p ＜ 0.01).
The above is only the preferred embodiment of the present invention, it is noted that come for those skilled in the art
Saying, under the premise without departing from the principles of the invention, it is also possible to make some improvements and modifications, these improvements and modifications also should be regarded as
Protection scope of the present invention.
Claims (10)
1. a prevention and the microalgae compositions for the treatment of airway inflammation, it is characterised in that: include the A that mass ratio is 10:1 ~ 1:10
Component and B component；Described component A is spirulina and mutation thereof and mutation mutation, and B component is monospore algae and mutation thereof and mutation becomes
Kind.
2. prevention as claimed in claim 1 and the microalgae compositions for the treatment of airway inflammation, it is characterised in that: described component A and B
The mass ratio of component is 1:1.
3. prevention as claimed in claim 1 and the microalgae compositions for the treatment of airway inflammation, it is characterised in that: in described component A
Spirulina includes Arthrospira and Spirullina.
4. prevention as claimed in claim 3 and the microalgae compositions for the treatment of airway inflammation, it is characterised in that: described Arthrospira
Including short arthrospira, Jian Shi arthrospira, Gas Vesicle Protein From Arthrospira maxima, transparent arthrospira, Obtusatus arthrospira, small-sized rotation shape arthrospira, rotation shape
Arthrospira and small arthrospira.
5. prevention as claimed in claim 3 and the microalgae compositions for the treatment of airway inflammation, it is characterised in that: described Spirullina
Including huge spirulina, Ge Shi spirulina, Qiang Shi spirulina, toroidal algae, loose spirulina, loose spirulina, huge spiral shell
Rotation algae, spirulina maxim, Meng Shi spirulina, Nuo Shi spirulina, seemingly quiver spirulina, spirulina plalensis, seemingly revolve spirulina, salt pool spiral shell
Rotation algae, careful spirulina, compact spiral algae, gentle helix algae, Sa Shi spirulina, mud pool spirulina and purple spirulina.
6. prevention as claimed in claim 1 and the microalgae compositions for the treatment of airway inflammation, it is characterised in that: in described B component
Monospore algae can be replaced micro-plan ball algae, Nitzschia closterium minutissima or Phaeodactylum.
7. one kind comprises the preparation of microalgae compositions described in claim 1, it is characterised in that: comprise the algae powder of component A and B component
And pharmaceutically acceptable adjuvant or comprise the fat extract of component A and B component and pharmaceutically acceptable adjuvant；Described fat
The consumption of extract is calculated by algae powder equivalent.
8. the preparation of microalgae compositions as claimed in claim 7, it is characterised in that: described preparation formulation is oral or external system
Agent.
9. the microalgae compositions as claimed in claim 1 application in preparation prevention and treatment airway inflammation disease medicament.
Apply the most as claimed in claim 9, it is characterised in that: described airway inflammation disease is bronchial asthma, chronic resistance
Plug property lung disease, acute lung injury and acute respiratory failure syndrome.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610458777.1A CN105998086A (en) | 2016-06-22 | 2016-06-22 | Microalgae composition for preventing and treating airway inflammation as well as preparation and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610458777.1A CN105998086A (en) | 2016-06-22 | 2016-06-22 | Microalgae composition for preventing and treating airway inflammation as well as preparation and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105998086A true CN105998086A (en) | 2016-10-12 |
Family
ID=57086568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610458777.1A Pending CN105998086A (en) | 2016-06-22 | 2016-06-22 | Microalgae composition for preventing and treating airway inflammation as well as preparation and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105998086A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115666610A (en) * | 2020-05-19 | 2023-01-31 | 瓦克萨科技有限公司 | Photosynthetic controlled spirulina extracts for the treatment of cytokine storm syndrome |
-
2016
- 2016-06-22 CN CN201610458777.1A patent/CN105998086A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| 刘洪岩等: "β-胡萝卜素的研究进展", 《盐业与化工》 * |
| 朱茂祥等: "富硒螺旋藻对60Co γ线胸部照射大鼠诱发肺炎的防治作用", 《军事医学科学院院报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115666610A (en) * | 2020-05-19 | 2023-01-31 | 瓦克萨科技有限公司 | Photosynthetic controlled spirulina extracts for the treatment of cytokine storm syndrome |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gundeti et al. | AYUSH 64, a polyherbal Ayurvedic formulation in Influenza-like illness-Results of a pilot study | |
| Li et al. | Cornuside inhibits mast cell-mediated allergic response by down-regulating MAPK and NF-κB signaling pathways | |
| Zhong et al. | Integrative medicine in allergy and immunology | |
| Chen et al. | Apigenin attenuates allergic responses of ovalbumin-induced allergic rhinitis through modulation of Th1/Th2 responses in experimental mice | |
| Wu et al. | Fucoxanthin ameliorates oxidative stress and airway inflammation in tracheal epithelial cells and asthmatic mice | |
| CN105169096A (en) | Medicine composition for treating gout or/and hyperuricemia | |
| Kim et al. | Britanin attenuates ovalbumin-induced airway inflammation in a murine asthma model | |
| Shou et al. | Total glucosides of peony improve ovalbumin-induced allergic asthma by inhibiting mast cell degranulation | |
| Khazdair et al. | The effect of Zataria multiflora on inflammatory cytokine and respiratory symptoms in veterans exposed to sulfur mustard | |
| Boskabady et al. | The effect of crocus sativus (saffron) on the respiratory system: traditional and experimental evidence | |
| Zhang et al. | Protective effect of Asarum sieboldii essential oil on ovalbumin induced allergic rhinitis in rat | |
| Alavinezhad et al. | Zataria multiflora affects clinical symptoms, oxidative stress and cytokines in asthmatic patient: a randomized, double blind, placebo-controlled, phase II clinical trial | |
| Chen et al. | Antioxidant and anti‑inflammatory effects of Schisandra and Paeonia extracts in the treatment of asthma | |
| Zhong et al. | Biochemical analysis reveals the systematic response of motion sickness mice to ginger (Zingiber officinale) extract's amelioration effect | |
| Yin et al. | A proprietary herbal drug Young Yum Pill ameliorates chronic fatigue syndrome in mice | |
| CN105998086A (en) | Microalgae composition for preventing and treating airway inflammation as well as preparation and application thereof | |
| Lin et al. | Traditional herbal medicine and allergic asthma | |
| Qin et al. | Effects of Gui Zhi Ma Huang Ge Ban Tang on the TLR7 pathway in influenza virus infected mouse lungs in a cold environment | |
| Kim et al. | Acute oral toxicity of Insampaedok-san, a traditional herbal formula, in rats and its protective effects against ovalbumin-induced asthma via anti-inflammatory and antioxidant properties | |
| CN105412281A (en) | Traditional Chinese medicinal composition for treating allergic asthma and preparation method thereof | |
| CN109394746A (en) | Ethyl sulfuric acid ammonium is in preparation for preventing or treating the application in diseases associated with inflammation drug | |
| CN105497167A (en) | New application of radix ranunculi ternate in preparation of medicine for treating and/or preventing ulcerative colitis | |
| CN106491957B (en) | It is a kind of for treating the preparation method of the Chinese medicine composition of bronchial asthma | |
| Shi et al. | Investigation of the Immunoprotective Effect of Zinc on Ovalbumin Induced BALB/C Male Mice Based on NF-KB Signaling Pathway | |
| CN103989931A (en) | Traditional Chinese medicine for treating infantile cough and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20161012 |
|
| WD01 | Invention patent application deemed withdrawn after publication |